13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001819257
Total reported value
$645.5M
$645.5M
24 檔
42.6%
As reported in its official Q3 2025 Form 13F filing, Patient Square Capital LP's tracked investment portfolio stood at $645.5M with 24 total positions.
Patient Square Capital LP executed strategic sector rebalancing during Q3 2025, establishing 11 new positions while fully exiting 6 holdings and trimming 10 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 50.51% | +3.84% | — | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 12.57% | -4.57% | EXIT | |
| 3 | EYPT | Eyepoint Inc | Stock-Other | 3.85% | -0.22% | -25.21% | |
| 4 | ABVX | Abivax Sa-adr | Stock-Other | 3.45% | +1.86% | — | |
| 5 | CDTX | Cidara Therapeutics Inc | Stock-Other | 3.10% | — | +706.67% | |
| 6 | ARGX | Argenx Se - Adr | Stock-Healthcare | 3.06% | -1.45% | -46.55% | |
| 7 | LQDA | Liquidia CORP | Stock-Other | 2.43% | — | -60.78% | |
| 8 | PHVS | Pharvaris N.V. | Stock-Other | 2.30% | +1.13% | +41.39% | |
| 9 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.24% | — | -12.56% | |
| 10 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.04% | +0.95% | -8.11% | |
| 11 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.44% | — | -4.23% | |
| 12 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.40% | -0.64% | -33.86% | |
| 13 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.37% | +0.28% | +2.03% | |
| 14 | CELC | Celcuity Inc | Stock-Other | 1.32% | -1.92% | EXIT | |
| 15 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.32% | +0.23% | — | |
| 16 | IRON | Disc Medicine Inc | Stock-Other | 1.31% | — | — | |
| 17 | QURE | uniQure N.V. | Stock-Other | 1.17% | — | — | |
| 18 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.15% | — | — | |
| 19 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.08% | — | +6.05% | |
| 20 | ALLO | Allogene Therapeutics Inc | Stock-Other | 0.99% | +0.14% | +13.15% | |
| 21 | ASMB | Assembly Biosciences Inc | Stock-Other | 0.93% | -0.67% | EXIT | |
| 22 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.34% | — | — | |
| 23 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.32% | -1.20% | EXIT | |
| 24 | GERN | Geron CORP | Stock-Other | 0.31% | — | +18.02% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +2.2% | -9.03% | Trim |
| 2 | PHVS | Pharvaris N.V. | +0.7% | +41.39% | Add |
| 3 | EYPT | Eyepoint Inc | +0.5% | -25.21% | Trim |
| 4 | MIRM | Mirum Pharmaceuticals Inc | -0.1% | -8.11% | Trim |
| 5 | KYMR | Kymera Therapeutics Inc | -0.2% | -33.86% | Trim |
| 6 | AGIO | Agios Pharmaceuticals Inc | -0.3% | -4.23% | Trim |
| 7 | IRON | Disc Medicine Inc | -0.4% | — | Trim |
| 8 | ALLO | Allogene Therapeutics Inc | -0.4% | +13.15% | Add |
| 9 | OCUL | Ocular Therapeutix Inc | -0.6% | -12.56% | Trim |
| 10 | ELVN | Enliven Therapeutics Inc | -0.7% | +2.03% | Trim |
| 11 | NRIX | Nurix Therapeutics Inc | -1.1% | +6.05% | Trim |
| 12 | ROIV | Roivant Sciences Ltd. | -1.6% | — | Unchanged |
| 13 | LQDA | Liquidia CORP | -6.9% | -60.78% | Trim |
| 14 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 15 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 16 | ARGX | Argenx Se - Adr | — | NEW | New buy |
| 17 | CGEM | Cullinan Therapeutics Inc | — | EXIT | Sold out |
| 18 | SRRK | Scholar Rock Holding CORP | — | EXIT | Sold out |
| 19 | CELC | Celcuity Inc | — | NEW | New buy |
| 20 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 21 | QURE | uniQure N.V. | — | NEW | New buy |
| 22 | AMLX | Amylyx Pharmaceuticals Inc | — | NEW | New buy |
| 23 | ASMB | Assembly Biosciences Inc | — | NEW | New buy |
| 24 | 2655787D | Blueprint Medicines CORP | — | EXIT | Sold out |
| 25 | NTLA | Intellia Therapeutics Inc | — | EXIT | Sold out |
| 26 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 27 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
| 28 | CATX | Perspective Therapeutics Inc | — | NEW | New buy |
| 29 | GERN | Geron CORP | — | NEW | New buy |
| 30 | VYNE | Vyne Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Patient Square Capital LP reported a total U.S. public equity portfolio value of $645.5M across 24 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ROIV, INSM, EYPT) accounted for 42.6% of total reported equity market value during Q3 2025.
Top New Position Initiated
ABVX
市值: $12.9M
Top Position Liquidated / Trimmed
CGEM
前期市值: $6.7M
During Q3 2025, Patient Square Capital LP's top holdings by market value included ROIV (50.5%)、INSM (12.6%)、EYPT (3.9%). The largest single position, ROIV, represented 50.5% of total portfolio value.
In Q3 2025, Patient Square Capital LP made 29 total portfolio adjustments, initiating 11 new buys, adding to 2 positions, trimming 10 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.